<DOC>
	<DOCNO>NCT01135914</DOCNO>
	<brief_summary>To evaluate , specifically within Canadian medical environment , efficacy , safety cost-efficacy ranibizumab administer either combination therapy ( ranibizumab plus laser photocoagulation ) , monotherapy comparison current standard care ( laser photocoagulation monotherapy ) , patient visual impairment due DME .</brief_summary>
	<brief_title>Safety , Efficacy Cost-efficacy Ranibizumab ( Monotherapy Combination With Laser ) Treatment Diabetic Macular Edema ( DME )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Stable Type 1 Type 2 diabetes mellitus Visual impairment due focal diffuse DME least one eye Active condition study eye could prevent improvement visual acuity study treatment Active eye infection inflammation History stroke , renal failure uncontrolled hypertension Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>DME</keyword>
	<keyword>visual impairment</keyword>
	<keyword>diabetes</keyword>
	<keyword>macular edema</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>laser</keyword>
	<keyword>photocoagulation</keyword>
	<keyword>retinopathy</keyword>
	<keyword>retina</keyword>
</DOC>